{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:25:51Z","timestamp":1794255951729,"version":"4.9.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["APQ-01680-23"],"award-info":[{"award-number":["APQ-01680-23"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["APQ-06678-24"],"award-info":[{"award-number":["APQ-06678-24"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013275","name":"Instituto Serrapilheira","doi-asserted-by":"publisher","award":["06\/2022"],"award-info":[{"award-number":["06\/2022"]}],"id":[{"id":"10.13039\/501100013275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-35790-1","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:04:38Z","timestamp":1772517878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Empagliflozin and intermittent fasting as a strategy to mitigate anthracycline-induced cardiotoxicity"],"prefix":"10.1038","volume":"16","author":[{"given":"Juliano Moreira","family":"Reis Filho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Lobo","family":"de Sousa Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Miranda","family":"Kangussu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Dantas","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielly Carvalho","family":"de Mattos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1vio Almeida","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Santos-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julliane V.","family":"Joviano-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"35790_CR1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41569-022-00698-6","volume":"19","author":"A Karlstaedt","year":"2022","unstructured":"Karlstaedt, A., Moslehi, J. & de Boer, R. A. Cardio-onco-metabolism: Metabolic remodelling in cardiovascular disease and cancer. Nat. Rev. Cardiol. 19, 414\u2013425 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"35790_CR2","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000521680","volume":"147","author":"KD Boudoulas","year":"2022","unstructured":"Boudoulas, K. D. et al. Cardiovascular disease, cancer, and multimorbidity interactions: Clinical implications. Cardiology 147, 196\u2013206 (2022).","journal-title":"Cardiology"},{"key":"35790_CR3","first-page":"459","volume":"89","author":"GP Mazzarello","year":"1998","unstructured":"Mazzarello, G. P. & Morra, L. Anthracyclines and the heart. Recenti Prog Med. 89, 459\u2013464 (1998).","journal-title":"Recenti Prog Med."},{"key":"35790_CR4","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1039\/D1NP00059D","volume":"39","author":"MB Hulst","year":"2022","unstructured":"Hulst, M. B., Grocholski, T., Neefjes, J. J. C., van Wezel, G. P. & Mets\u00e4-Ketel\u00e4, M. Anthracyclines: Biosynthesis, engineering and clinical applications. Nat. Prod. Rep. 39, 814\u2013841 (2022).","journal-title":"Nat. Prod. Rep."},{"key":"35790_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s11906-010-0146-y","volume":"12","author":"CA Geisberg","year":"2010","unstructured":"Geisberg, C. A. & Sawyer, D. B. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr. Hypertens. Rep. 12, 404\u2013410 (2010).","journal-title":"Curr. Hypertens. Rep."},{"key":"35790_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","volume":"7","author":"M Volkova","year":"2011","unstructured":"Volkova, M. & Russell, R. 3 Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment. Curr. Cardiol. Rev. 7, 214\u2013220 (2011).","journal-title":"Curr. Cardiol. Rev."},{"key":"35790_CR7","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.36660\/abc.20201006","volume":"115","author":"LA Hajjar","year":"2020","unstructured":"Hajjar, L. A. et al. Brazilian Cardio-oncology guideline \u2013\u20092020. Arq. Bras. Cardiol. 115, 1006\u20131043 (2020).","journal-title":"Arq. Bras. Cardiol."},{"key":"35790_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-3-030-43032-0_15","volume":"1257","author":"A Bhagat","year":"2020","unstructured":"Bhagat, A. & Kleinerman, E. S. Anthracycline-Induced cardiotoxicity: Causes, mechanisms, and prevention. Adv. Exp. Med. Biol. 1257, 181\u2013192 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"35790_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","volume":"4","author":"T Omland","year":"2022","unstructured":"Omland, T., Heck, S. L. & Gulati, G. The role of cardioprotection in cancer therapy cardiotoxicity: JACC: Cardiooncology State-of-the-Art review. JACC CardioOncol. 4, 19\u201337 (2022).","journal-title":"JACC CardioOncol"},{"key":"35790_CR10","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon, A. R. et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur. Heart J. 43, 4229\u20134361 (2022).","journal-title":"Eur. Heart J."},{"key":"35790_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jaccao.2019.08.004","volume":"1","author":"DL Bhatt","year":"2019","unstructured":"Bhatt, D. L. Birth and maturation of cardio-oncology. JACC. CardioOncol. 1, 114\u2013116 (2019). https:\/\/doi.org\/10.1016\/j.jaccao.2019.08.004","journal-title":"JACC. CardioOncol."},{"key":"35790_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2019","unstructured":"Cosentino, F. et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 41, 255\u2013323 (2020). (2019).","journal-title":"Eur. Heart J."},{"key":"35790_CR13","doi-asserted-by":"crossref","unstructured":"Standards of Medical Care in Diabetes-2022 abridged for primary care providers. Clin. Diabetes. 40, 10\u201338 (2022).","DOI":"10.2337\/cd22-as01"},{"key":"35790_CR14","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"key":"35790_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","volume":"22","author":"K Damman","year":"2020","unstructured":"Damman, K. et al. Randomized, double-blind, placebo\u2010controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA\u2010RESPONSE\u2010AHF). Eur. J. Heart Fail. 22, 713\u2013722 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"35790_CR16","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.3390\/ijms26104780","volume":"26","author":"A Greco","year":"2025","unstructured":"Greco, A. et al. SGLT2 inhibitors in cancer patients: A comprehensive review of clinical, biochemical, and therapeutic implications in cardio-oncology. Int. J. Mol. Sci. 26, 4780 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"35790_CR17","doi-asserted-by":"crossref","unstructured":"Kahleova, H., Levin, S. & Barnard, N. Cardio-metabolic benefits of plant-based diets. Nutrients 9, (2017).","DOI":"10.3390\/nu9080848"},{"key":"35790_CR18","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1161\/CIRCRESAHA.116.307473","volume":"118","author":"H Mirzaei","year":"2016","unstructured":"Mirzaei, H., Di Biase, S. & Longo, V. D. Dietary interventions, cardiovascular aging, and disease: Animal models and human studies. Circ. Res. 118, 1612\u20131625 (2016).","journal-title":"Circ. Res."},{"key":"35790_CR19","doi-asserted-by":"crossref","unstructured":"Malinowski, B. et al. Intermittent fasting in cardiovascular disorders-An overview. Nutrients 11, (2019).","DOI":"10.3390\/nu11030673"},{"key":"35790_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.amjmed.2020.03.030","volume":"133","author":"TA Dong","year":"2020","unstructured":"Dong, T. A. et al. Intermittent fasting: A heart healthy dietary pattern? Am. J. Med. 133, 901\u2013907 (2020).","journal-title":"Am. J. Med."},{"key":"35790_CR21","first-page":"527","volume":"71","author":"KK Clifton","year":"2021","unstructured":"Clifton, K. K., Ma, C. X., Fontana, L. & Peterson, L. L. Intermittent fasting in the prevention and treatment of cancer. CA Cancer J. Clin. 71, 527\u2013546 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"35790_CR22","doi-asserted-by":"publisher","first-page":"e814s","DOI":"10.6061\/clinics\/2018\/e814s","volume":"73","author":"F Antunes","year":"2018","unstructured":"Antunes, F. et al. Autophagy and intermittent fasting: The connection for cancer therapy? Clin. (Sao Paulo). 73, e814s (2018).","journal-title":"Clin. (Sao Paulo)"},{"key":"35790_CR23","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1111\/cas.15492","volume":"113","author":"S Tiwari","year":"2022","unstructured":"Tiwari, S., Sapkota, N. & Han, Z. Effect of fasting on cancer: A narrative review of scientific evidence. Cancer Sci. 113, 3291\u20133302 (2022).","journal-title":"Cancer Sci."},{"key":"35790_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13063-019-3928-9","volume":"21","author":"LS Bahr","year":"2020","unstructured":"Bahr, L. S. et al. Ketogenic diet and fasting diet as nutritional approaches in multiple sclerosis (NAMS): Protocol of a randomized controlled study. Trials 21, 3 (2020).","journal-title":"Trials"},{"key":"35790_CR25","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1161\/CIRCRESAHA.123.321872","volume":"132","author":"TR Matsuura","year":"2023","unstructured":"Matsuura, T. R., Puchalska, P., Crawford, P. A. & Kelly, D. P. Ketones and the heart: Metabolic principles and therapeutic implications. Circ. Res. 132, 882\u2013898 (2023).","journal-title":"Circ. Res."},{"key":"35790_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1023\/B:BREA.0000014037.48744.fa","volume":"83","author":"MN Harvie","year":"2004","unstructured":"Harvie, M. N., Campbell, I. T., Baildam, A. & Howell, A. Energy balance in early breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res. Treat. 83, 201\u2013210 (2004).","journal-title":"Breast Cancer Res. Treat."},{"key":"35790_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1467-789X.2010.00805.x","volume":"12","author":"V Vance","year":"2011","unstructured":"Vance, V., Mourtzakis, M., McCargar, L. & Hanning, R. Weight gain in breast cancer survivors: Prevalence, pattern and health consequences. Obes. Rev. 12, 282\u2013294 (2011).","journal-title":"Obes. Rev."},{"key":"35790_CR28","doi-asserted-by":"publisher","first-page":"670479","DOI":"10.3389\/fphar.2021.670479","volume":"12","author":"EY Podyacheva","year":"2021","unstructured":"Podyacheva, E. Y., Kushnareva, E. A., Karpov, A. A. & Toropova, Y. G. Analysis of models of Doxorubicin-Induced cardiomyopathy in rats and Mice. A modern view from the perspective of the pathophysiologist and the clinician. Front. Pharmacol. 12, 670479 (2021).","journal-title":"Front. Pharmacol."},{"key":"35790_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cmet.2018.08.004","volume":"29","author":"A Chaix","year":"2019","unstructured":"Chaix, A., Lin, T., Le, H. D., Chang, M. W. & Panda, S. Time-Restricted feeding prevents obesity and metabolic syndrome in mice lacking a circadian clock. Cell. Metab. 29, 303\u2013319e4 (2019).","journal-title":"Cell. Metab."},{"key":"35790_CR30","first-page":"217","volume":"9","author":"AK Azemi","year":"2022","unstructured":"Azemi, A. K., Siti-Sarah, A. R., Mokhtar, S. S. & Rasool, A. H. G. Time-Restricted feeding improved vascular endothelial function in a high-fat diet-induced obesity rat model. Vet. Sci. 9, 217 (2022).","journal-title":"Vet. Sci."},{"key":"35790_CR31","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1097\/HJH.0000000000003200","volume":"40","author":"BM Sims","year":"2022","unstructured":"Sims, B. M. et al. Time restricted feeding decreases renal innate immune cells and blood pressure in hypertensive mice. J. Hypertens. 40, 1960\u20131968 (2022).","journal-title":"J. Hypertens."},{"key":"35790_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40519-024-01709-w","volume":"29","author":"Z Bahadoran","year":"2024","unstructured":"Bahadoran, Z., Mirmiran, P., Kashfi, K. & Ghasemi, A. Effects of time-restricted feeding (TRF)-model of intermittent fasting on adipose organ: A narrative review. Eat. Weight Disorders - Stud. Anorexia Bulimia Obes. 29, 77 (2024).","journal-title":"Eat. Weight Disorders - Stud. Anorexia Bulimia Obes."},{"key":"35790_CR33","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/nu12030874","volume":"12","author":"SA Lee","year":"2020","unstructured":"Lee, S. A. et al. Determinants of adherence in Time-Restricted feeding in older adults: Lessons from a pilot study. Nutrients 12, 874 (2020).","journal-title":"Nutrients"},{"key":"35790_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejphar.2010.05.046","volume":"641","author":"M Rahimi-Balaei","year":"2010","unstructured":"Rahimi-Balaei, M. et al. The modulatory effect of lithium on doxorubicin-induced cardiotoxicity in rat. Eur. J. Pharmacol. 641, 193\u2013198 (2010).","journal-title":"Eur. J. Pharmacol."},{"key":"35790_CR35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1088\/0967-3334\/36\/4\/727","volume":"36","author":"T Lon\u010dar-Turukalo","year":"2015","unstructured":"Lon\u010dar-Turukalo, T. et al. Heart rate dynamics in doxorubicin-induced cardiomyopathy. Physiol. Meas. 36, 727\u2013739 (2015).","journal-title":"Physiol. Meas."},{"key":"35790_CR36","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1590\/1678-6160-pvb-6029","volume":"39","author":"AFM Botelho","year":"2019","unstructured":"Botelho, A. F. M. et al. Non-invasive ECG recording and QT interval correction assessment in anesthetized rats and mice. Pesquisa Vet. Brasileira. 39, 409\u2013415 (2019).","journal-title":"Pesquisa Vet. Brasileira"},{"key":"35790_CR37","first-page":"1","volume":"16","author":"A Santos-Miranda","year":"2020","unstructured":"Santos-Miranda, A. et al. Reactive oxygen species and nitric oxide imbalances lead to in vivo and in vitro arrhythmogenic phenotype in acute phase of experimental Chagas disease. PLoS Pathog. 16, 1\u201327 (2020).","journal-title":"PLoS Pathog."},{"key":"35790_CR38","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12916-021-02185-0","volume":"19","author":"H Kolb","year":"2021","unstructured":"Kolb, H. et al. Ketone bodies: From enemy to friend and guardian Angel. BMC Med. 19, 313 (2021).","journal-title":"BMC Med."},{"key":"35790_CR39","doi-asserted-by":"crossref","unstructured":"Mascolo, A. et al. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Front. Cardiovasc. Med. 9, (2022).","DOI":"10.3389\/fcvm.2022.1010693"},{"key":"35790_CR40","doi-asserted-by":"publisher","DOI":"10.12890\/2023_004216","author":"L Posado-Dom\u00ednguez","year":"2023","unstructured":"Posado-Dom\u00ednguez, L. et al. Complications secondary to the use of SGLT2 inhibitors in oncological patients: A series of 5 cases. Eur. J. Case Rep. Intern. Med. https:\/\/doi.org\/10.12890\/2023_004216 (2023).","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"35790_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","volume":"12","author":"V Avula","year":"2024","unstructured":"Avula, V. et al. SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy\u2013related cardiac dysfunction. JACC Heart Fail. 12, 67\u201378 (2024).","journal-title":"JACC Heart Fail."},{"key":"35790_CR42","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.3390\/nu14112299","volume":"14","author":"S Uldal","year":"2022","unstructured":"Uldal, S., Clemmensen, K. K. B., Persson, F., F\u00e6rch, K. & Quist, J. S. Is time-restricted eating safe in the treatment of type 2 diabetes?\u2014A review of intervention studies. Nutrients 14, 2299 (2022).","journal-title":"Nutrients"},{"key":"35790_CR43","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","volume":"77","author":"M Packer","year":"2021","unstructured":"Packer, M. et al. Empagliflozin in patients with heart Failure, reduced ejection Fraction, and volume overload. J. Am. Coll. Cardiol. 77, 1381\u20131392 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"35790_CR44","doi-asserted-by":"publisher","first-page":"111229","DOI":"10.1016\/j.cbi.2024.111229","volume":"403","author":"RR Soares","year":"2024","unstructured":"Soares, R. R., Viggiani, L. F., Filho, R., Joviano-Santos, J. V. & J. M. & Cardioprotection of Canagliflozin, Dapagliflozin, and empagliflozin: Lessons from preclinical studies. Chem. Biol. Interact. 403, 111229 (2024).","journal-title":"Chem. Biol. Interact."},{"key":"35790_CR45","doi-asserted-by":"publisher","first-page":"7477","DOI":"10.3390\/ijms25137477","volume":"25","author":"R Vitale","year":"2024","unstructured":"Vitale, R., Marzocco, S. & Popolo, A. Role of oxidative stress and inflammation in doxorubicin-induced cardiotoxicity: A brief account. Int. J. Mol. Sci. 25, 7477 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"35790_CR46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2023.02.019","volume":"185","author":"WCM Dempke","year":"2023","unstructured":"Dempke, W. C. M. et al. Anthracycline-induced cardiotoxicity\u2014Are we about to clear this hurdle? Eur. J. Cancer. 185, 94\u2013104 (2023).","journal-title":"Eur. J. Cancer"},{"key":"35790_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","volume":"18","author":"HC Lee","year":"2019","unstructured":"Lee, H. C. et al. The sodium\u2013glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc. Diabetol. 18, 45 (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"35790_CR48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/ph18030313","volume":"18","author":"F Rolski","year":"2025","unstructured":"Rolski, F. & M\u0105czewski, M. Cardiac fibrosis: Mechanistic discoveries linked to SGLT2 inhibitors. Pharmaceuticals 18, 313 (2025).","journal-title":"Pharmaceuticals"},{"key":"35790_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12933-023-01756-0","volume":"22","author":"CC Chung","year":"2023","unstructured":"Chung, C. C. et al. Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger Inhibition and modulation of the calcium homeostasis. Cardiovasc. Diabetol. 22, 27 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"35790_CR50","doi-asserted-by":"crossref","unstructured":"Koizumi, T. et al. Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats. Front. Cardiovasc. Med. 10, (2023).","DOI":"10.3389\/fcvm.2023.1005408"},{"key":"35790_CR51","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185\u2013229 (2004).","journal-title":"Pharmacol. Rev."},{"key":"35790_CR52","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1111\/dom.14517","volume":"23","author":"K Thiele","year":"2021","unstructured":"Thiele, K. et al. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study. Diabetes Obes. Metab. 23, 2814\u20132818 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"35790_CR53","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","volume":"141","author":"CD Mazer","year":"2020","unstructured":"Mazer, C. D. et al. Effect of empagliflozin on erythropoietin Levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation 141, 704\u2013707 (2020).","journal-title":"Circulation"},{"key":"35790_CR54","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3945\/ajcn.115.109553","volume":"102","author":"BD Horne","year":"2015","unstructured":"Horne, B. D., Muhlestein, J. B. & Anderson, J. L. Health effects of intermittent fasting: Hormesis or harm? A systematic review. Am. J. Clin. Nutr. 102, 464\u2013470 (2015).","journal-title":"Am. J. Clin. Nutr."},{"key":"35790_CR55","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s13668-025-00666-9","volume":"14","author":"\u00c1A Vergara Nieto","year":"2025","unstructured":"Vergara Nieto, \u00c1. A., Diaz, A. H., Hern\u00e1ndez, M. & Sagredo, D. A narrative review about metabolic pathways, molecular mechanisms and clinical implications of intermittent fasting as autophagy promotor. Curr. Nutr. Rep. 14, 78 (2025).","journal-title":"Curr. Nutr. Rep."},{"key":"35790_CR56","first-page":"513","volume":"356","author":"WKE Ip","year":"2017","unstructured":"Ip, W. K. E., Hoshi, N., Shouval, D. S., Snapper, S. & Medzhitov, R. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science (1979). 356, 513\u2013519 (2017).","journal-title":"Science (1979)"},{"key":"35790_CR57","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/08977194.2011.595714","volume":"29","author":"A Biernacka","year":"2011","unstructured":"Biernacka, A., Dobaczewski, M. & Frangogiannis, N. G. TGF-\u03b2 signaling in fibrosis. Growth Factors. 29, 196\u2013202 (2011).","journal-title":"Growth Factors"},{"key":"35790_CR58","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.yjmcc.2010.10.033","volume":"51","author":"M Dobaczewski","year":"2011","unstructured":"Dobaczewski, M., Chen, W. & Frangogiannis, N. G. Transforming growth factor (TGF)-\u03b2 signaling in cardiac remodeling. J. Mol. Cell. Cardiol. 51, 600\u2013606 (2011).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"35790_CR59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jacbts.2024.08.003","volume":"10","author":"PE Nikolaou","year":"2025","unstructured":"Nikolaou, P. E. et al. Empagliflozin in acute myocardial infarction reduces No-Reflow and preserves cardiac function by preventing endothelial damage. JACC Basic. Transl Sci. 10, 43\u201361 (2025).","journal-title":"JACC Basic. Transl Sci."},{"key":"35790_CR60","doi-asserted-by":"publisher","first-page":"120404","DOI":"10.1016\/j.atherosclerosis.2025.120404","volume":"407","author":"N Mylonas","year":"2025","unstructured":"Mylonas, N. et al. Empagliflozin restores cardiac metabolism and suppresses immune activation in acute myocardial infarction. Atherosclerosis 407, 120404 (2025).","journal-title":"Atherosclerosis"},{"key":"35790_CR61","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41569-025-01165-8","volume":"22","author":"I Andreadou","year":"2025","unstructured":"Andreadou, I. et al. Immunometabolism in heart failure. Nat. Rev. Cardiol. 22, 751\u2013772 (2025).","journal-title":"Nat. Rev. Cardiol."},{"key":"35790_CR62","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40959-021-00090-2","volume":"7","author":"R Araujo-Gutierrez","year":"2021","unstructured":"Araujo-Gutierrez, R. et al. Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity. Cardio-Oncology 7, 4 (2021).","journal-title":"Cardio-Oncology"},{"key":"35790_CR63","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bbrc.2007.12.081","volume":"369","author":"AN Chang","year":"2008","unstructured":"Chang, A. N., Parvatiyar, M. S. & Potter, J. D. Troponin and cardiomyopathy. Biochem. Biophys. Res. Commun. 369, 74\u201381 (2008).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"35790_CR64","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","volume":"20","author":"V Quagliariello","year":"2021","unstructured":"Quagliariello, V. et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc. Diabetol. 20, 150 (2021).","journal-title":"Cardiovasc. Diabetol."},{"key":"35790_CR65","doi-asserted-by":"publisher","first-page":"116759","DOI":"10.1016\/j.biopha.2024.116759","volume":"176","author":"HY Chang","year":"2024","unstructured":"Chang, H. Y., Hsu, H. C., Fang, Y. H., Liu, P. Y. & Liu, Y. W. Empagliflozin attenuates doxorubicin-induced cardiotoxicity by inhibiting the JNK signaling pathway. Biomed. Pharmacother. 176, 116759 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"35790_CR66","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3892\/mmr.2024.13198","volume":"29","author":"A Malik","year":"2024","unstructured":"Malik, A., Bagchi, A., Jassal, D. & Singal, P. Doxorubicin-induced cardiomyopathy is mitigated by empagliflozin via the modulation of Endoplasmic reticulum stress pathways. Mol. Med. Rep. 29, 74 (2024).","journal-title":"Mol. Med. Rep."},{"key":"35790_CR67","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.cmet.2023.02.006","volume":"35","author":"M Ozcan","year":"2023","unstructured":"Ozcan, M. et al. Sustained alternate-day fasting potentiates doxorubicin cardiotoxicity. Cell. Metab. 35, 928\u2013942e4 (2023).","journal-title":"Cell. Metab."},{"key":"35790_CR68","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.3390\/nu16172921","volume":"16","author":"RR Andrews","year":"2024","unstructured":"Andrews, R. R., Anderson, K. R. & Fry, J. L. Sex-Specific variation in metabolic responses to diet. Nutrients 16, 2921 (2024).","journal-title":"Nutrients"},{"key":"35790_CR69","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.3390\/nu14214535","volume":"14","author":"M Torrens-Mas","year":"2022","unstructured":"Torrens-Mas, M. et al. Sex specific differences in response to calorie restriction in skeletal muscle of young rats. Nutrients 14, 4535 (2022).","journal-title":"Nutrients"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35790-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35790-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35790-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:04:11Z","timestamp":1775732651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35790-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["35790"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-35790-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11795"}}